In this issue:
[177Lu]Lu-PSMA-617 + enzalutamide for mCRPC
ADT with SBRT for hormone-sensitive oligorecurrent prostate cancer
High omega-3, low omega-6 diet with fish oil during AS
Radiographic progression without PSA progression after apalutamide
Intensified salvage therapy in PSArecurrent prostate cancer
Benefit of docetaxel + ADT predicted by ERG expression
Gleason Grade Group 1 reclassification after PI-RADS 5 findings
Hypofractionated dose escalation radiotherapy for high-risk prostate cancer
Prostate cancer-related events in mHSPC after ADT and radiation
Liquid biopsy in progressing patients starting docetaxel +/– enzalutamide
Please login below to download this issue (PDF)